Status:
COMPLETED
Neuroinflammation and Modulating Factors in Depression and HIV
Lead Sponsor:
University of Minnesota
Collaborating Sponsors:
National Institute of Mental Health (NIMH)
Conditions:
Depression
HIV
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Determine if depression, which persists after depression treatment at 26 weeks, is associated with increased innate inflammation in a prospective cohort of HIV-infected Ugandans receiving SSRIs in whi...
Detailed Description
Depression in HIV is a complex co-morbidity with both social factors such as stigma as well as biologic components. Disruptions in neurotransmitters such as serotonin and catecholamines are known to c...
Eligibility Criteria
Inclusion
- For the depressed patient arm,
- Newly-presenting clinic patients (\<3 months)
- Mild to Moderately-Severe Depressive Symptoms with PHQ-9 score \>5 but \<20
- Not suicidal (PHQ-9 question 9 score \>2)
- Not receiving antiretroviral therapy (ART) at screening
- Outpatient, not requiring hospitalization
- For the non-depressed patient arm,
- Newly-presenting clinic patients (\<3 months)
- Not suicidal (PHQ-9 question 9 score \>2)
- Not receiving antiretroviral therapy (ART) at screening
- Outpatient, not requiring hospitalization
Exclusion
- \- No additional exclusion criteria
Key Trial Info
Start Date :
February 1 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 9 2024
Estimated Enrollment :
109 Patients enrolled
Trial Details
Trial ID
NCT04286282
Start Date
February 1 2021
End Date
April 9 2024
Last Update
January 9 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Infectious Diseases Institute
Kampala, Uganda